Pharmaceuticals announced the pricing of an underwritten public offering of 13,158,000 shares of its common stock at a public ...

Pharmaceuticals announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the ...

US biotech Inovio (Nasdaq: INO) said it plans to offer and sell shares of its common stock in an underwritten public offering ...

The stock's rise snapped a four-day losing streak.

Investing.com -- INOVIO Pharmaceuticals Inc. (NASDAQ:INO) shares fell 10% after the biotechnology company announced the pricing of an underwritten public offering at $1.90 per share, representing a ...

Inovio Pharmaceuticals Inc. INO) on Monday reported a loss of $45.5 million in its third quarter.

Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review ...

The biotech sector has long offered investors high-risk, high-reward stocks. While large players are making headlines, the ...

INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and ...

Shares of Inovio Pharmaceuticals Inc. INO shed 2.88% to $2.36 Thursday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index COMP falling 1.57 ...

The study tests two interventions: Inotuzumab Ozogamicin, an experimental drug targeting CD22-positive B-cell precursor ALL, and the ALLR3 regimen, a standard chemotherapy treatment. Inotuzumab ...

SHELTON, CONNECTICUT / ACCESS Newswire / November 11, 2025 / NanoViricides, Inc. (the "Company"), today announced that it has entered into a securities purchase agreement with a single healthcare ...